Not logged inPredictive biomarkers and protein specific mismatch repair (MMR) loss in gastrointestinal (GI) tumours on immune checkpoint inhibitors (ICI): Correlation with survival
Le, H. M. L.; Paiva, R. V. D. S.; Farag, S.; Dadouli, K.; Ntellas, P.; Cunningham, D.; Starling, N.; Rao, S.; Fribbens, C.; Chau, I. .png)
Share.png)
SavePhase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGECartwright, E.; Slater, S.; Saffery, C.; Tran, A.; Turkes, F.; Smith, G.; Aresu, M.; Kohoutova, D.; Terlizzo, M.; Zhitkov, O.; Rana, I.; Johnston, E. W.; Sanna, I.; Smyth, E.; Mansoor, W.; Fribbens, C.; Rao, S.; Chau, I.; Starling, N.; Cunningham, D. Share Save The Gastrointestinal and Lymphoma Unit Advanced Nurse Practitioner role in clinical research at The Royal Marsden HospitalHobbis, L.; Duncan, J.; Kinnaird, F.; Fong, C.; Li, S.; Gordon, A.; Chau, I.; Starling, N.; Rao, S.; Watkins, D.; Fribbens, C.; Cunningham, D. Share Save EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinomaSlater, S.; Cartwright, E.; Saffery, C.; Tran, A.; Smith, G.; Bacason, M.; Zhitkov, O.; Rana, I.; Johnston, E.; Sanna, I.; Aresu, M.; Kohoutova, D.; Terlizzo, M.; Turkes, F.; Smyth, E.; Mansoor, W.; Fribbens, C.; Rao, S.; Watkins, D.; Starling, N.; Chau, I.; Cunningham, D. Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
